Year: 2014
Type: article
Abstract: As the need to develop a successful disease-modifying treatment for Alzheimer's disease (AD) becomes more urgent, imaging is increasingly used in therapeutic trials. We provide an overview of how the different imaging modalities are used in AD studies and the current regulatory guidelines for their use in clinical trials as endpoints. We review the current literature for results of imaging endpoints of efficacy and safety in published clinical trials. We start with trials in mild to moderate AD, where imaging (largely magnetic resonance imaging (MRI)) has long played a role in inclusion and exclusion criteria; more recently, MRI has been used to identify adverse events and to measure rates of brain atrophy. The advent of amyloid imaging using positron emission tomography has led to trials incorporating amyloid measurements as endpoints and incidentally to the recognition of the high proportion of amyloid-negative individuals that may be recruited into these trials. Ongoing and planned trials now commonly include multimodality imaging: amyloid positron emission tomography, MRI and other modalities. At the same time, the failure of recent large profile trials in mild to moderate AD together with the realisation that there is a long prodromal period to AD has driven a push to move studies to earlier in the disease. Imaging has particularly important roles, alongside other biomarkers, in assessing efficacy because conventional clinical outcomes may have limited ability to detect treatment effects in these early stages.
Source: Alzheimer s Research & Therapy
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Keywords: Alzheimer's disease, imaging endpoints, clinical trial endpoints, amyloid PET, brain atrophy, magnetic resonance imaging, multimodal imaging, disease-modifying therapy, early Alzheimer's disease, prodromal Alzheimer's disease, regulatory guidelines, biomarkers, treatment efficacy and safety
Open Access status: gold
Estimated APC paid: $4,290
Funders: National Institute for Health and Care Research, Brain Research Trust, University College London, Wolfson Foundation, University College London Hospitals NHS Foundation Trust, Medical Research Council, Engineering and Physical Sciences Research Council, FP7 Information and Communication Technologies
Awards: G1074010309, G1238216143, G1737639950, G1775974636, G1910368662, Detecting, tracking & modelling structural and functional brain imaging changes in Alzheimer's disease, NIHR Senior Investigator Award, Intelligent Imaging: Motion, Form and Function Across Scale, Computational models of neurodegenerative disease progression, G4421367155, G5183228286, G630566656, G6496510108, G7162635584, NIHR Senior Investigator Award, G861408993, G8642393552, EPICure@19 - the extremely preterm young adult
OpenAlex ID: W2096178982
